Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report

Phosphodiesterase 5 inhibitors lower both portal and pulmonary pressure in portopulmonary hypertension: a case report

<p>Abstract</p> <p>Background</p> <p>Portopulmonary hypertension (PPHTN) is a severe complication in liver cirrhosis. PDE5 inhibitors lower pulmonary arterial pressure (PAP) in PPHTN. However, their effect on portal hypertension has not yet been investigated.</p>...

Full description

Bibliographic Details
Main Authors:	Bremer Hinrich C, Kreisel Wolfgang, Roecker Kai, Dreher Michael, Koenig Daniel, Kurz-Schmieg Anna, Blum Hubert E, Roessle Martin, Deibert Peter
Format:	Article
Language:	English
Published:	BMC 2007-07-01
Series:	Journal of Medical Case Reports
Online Access:	http://www.jmedicalcasereports.com/content/1/1/46

Similar Items

Effectiveness of Phosphodiesterase-5 Inhibitor Therapy for Portopulmonary Hypertension
by: Jolene H Fisher, et al.
Published: (2015-01-01)

Phosphodiesterases in the Liver as Potential Therapeutic Targets of Cirrhotic Portal Hypertension
by: Wolfgang Kreisel, et al.
Published: (2020-08-01)

Portopulmonary hypertension caused by portal hypertension that is complicated by central diabetes insipidus
by: Tingting Zhao, et al.
Published: (2020-03-01)

Portopulmonary hypertension
by: Saleemi Sarfraz
Published: (2010-01-01)

Phosphodiesterase-5 inhibitors have distinct effects on the hemodynamics of the liver
by: Dunkern Torsten, et al.
Published: (2009-09-01)

Prevalence and Associated Factors of Portopulmonary Hypertension in Patients with Portal Hypertension: A Case-Control Study
by: Yueming Shao, et al.
Published: (2021-01-01)

Portopulmonary hypertension in a child
by: D. I. Sadykova, et al.
Published: (2016-11-01)

Hipertensão portopulmonar Portopulmonary hypertension
by: Eduardo Garcia, et al.
Published: (2005-04-01)

Bosentan for the treatment of portopulmonary hypertension
by: Tempe Deepak, et al.
Published: (2008-01-01)

Portopulmonary hypertension: state of the art
by: Mateo Porres-Aguilar, et al.
Published: (2008-10-01)

Portopulmonary Hypertension: From Bench to Bedside
by: Christopher Thomas, et al.
Published: (2020-11-01)

Causes and Circumstances of Death in Portopulmonary Hypertension
by: Sandeep Sahay, MD, et al.
Published: (2021-07-01)

Review: Portopulmonary hypertension: challenges in diagnosis and management
by: Patrick J. Troy, et al.
Published: (2009-09-01)

The portopulmonary hypertension: an overview from diagnosis to treatment
by: Andrea Salzano, et al.
Published: (2015-11-01)

The clinical characteristics, treatment, and survival of portopulmonary hypertension in Japan
by: Yukiko Takahashi, et al.
Published: (2021-03-01)

Saudi Guidelines on the Diagnosis and Treatment of Pulmonary Hypertension: Portopulmonary hypertension
by: Sarfraz Saleemi, et al.
Published: (2014-01-01)

Prevalence and Prognosis of Portopulmonary Hypertension in 223 Liver Transplant Recipients
by: Jian Li, et al.
Published: (2018-01-01)

The early outcomes of candidates with portopulmonary hypertension after liver transplantation
by: Bingsong Huang, et al.
Published: (2018-06-01)

Portopulmonary Hypertension: A Survey of Practice Patterns and Provider Attitudes
by: Hilary M. DuBrock, MD, et al.
Published: (2019-06-01)

Portopulmonary hypertension and hepatopulmonary syndrome: a clinician-oriented overview
by: Jose T. Altamirano, et al.
Published: (2012-09-01)

The use of sildenafil to treat portopulmonary hypertension prior to liver transplantation
by: Ian S.H. Cadden;, et al.
Published: (2009-04-01)

Living donor liver transplantation in a patient with severe portopulmonary hypertension
by: Shweta A Singh, et al.
Published: (2020-01-01)

Left main coronary artery compression in a patient with portopulmonary hypertension
by: Iara Teixeira de Araújo, et al.

Perioperative management with phosphodiesterase type 5 inhibitor and prostaglandin E1 for moderate portopulmonary hypertension following adult-to-adult living-donor liver transplantation: a case report
by: Takashi Onoe, et al.
Published: (2018-02-01)

MELD exception for liver transplantation in portopulmonary hypertension: current implementation and future considerations
by: Mateo Porres-Aguilar, M.D., FACP, et al.
Published: (2014-11-01)

Role of echocardiography in screening for portopulmonary hypertension in liver transplant candidates: a meta-analysis
by: Xin Yin, et al.
Published: (2020-05-01)

Transition from Hepatopulmonary Syndrome to Portopulmonary Hypertension: A Case Series of 3 Patients
by: Radhika Zopey, et al.
Published: (2013-01-01)

Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studies
by: Rodrigo Cartin-Ceba, et al.
Published: (2018-05-01)

Differential diagnosis of hepatopulmonary syndrome (HPS): Portopulmonary hypertension (PPH) and hereditary hemorrhagic telangiectasia (HHT)
by: Inna Krynytska, et al.
Published: (2017-11-01)

Health disparities and treatment approaches in portopulmonary hypertension and idiopathic pulmonary arterial hypertension: an analysis of the Pulmonary Hypertension Association Registry
by: Hilary M. DuBrock, et al.
Published: (2021-06-01)

An excerpt of International Liver Transplant Society Practice Guidelines: diagnosis and management of hepatopulmonary syndrome and portopulmonary hypertension (2016)
by: LIU Yijun, et al.
Published: (2016-10-01)

Protocol: Prospective observational study investigating the prevalence and clinical outcome of portopulmonary hypertension in Japanese patients with chronic liver disease.
by: Shun-Ichi Wakabayashi, et al.
Published: (2021-01-01)

Outcomes of Liver Transplantation in Treated Portopulmonary Hypertension Patients With a Mean Pulmonary Arterial Pressure ≥35 mm Hg
by: Hilary M. DuBrock, MD, et al.
Published: (2020-12-01)

The role of phosphodiesterase 3, phosphodiesterase 5, and the inhibitory γ subunit of the retinal cyclic GMP phosphodiesterase, in pulmonary hypertension
by: Murray, Fiona
Published: (2003)

What do we take consideration in the patient who has an unpredicted severe portopulmonary hypertension in liver transplantation?: a case report
by: HyunJung Koh, et al.
Published: (2015-02-01)

Effect of PAH Specific Therapy on Pulmonary Hemodynamics and Six-Minute Walk Distance in Portopulmonary Hypertension: A Systematic Review and Meta-Analysis
by: Muhammad Faisal, et al.
Published: (2014-01-01)

Phosphodiesterase 3/4 inhibitor zardaverine exhibits potent and selective antitumor activity against hepatocellular carcinoma both in vitro and in vivo independently of phosphodiesterase inhibition.
by: Liping Sun, et al.
Published: (2014-01-01)

Validation of phosphodiesterase isozymes as targets for pulmonary hypertension
by: Trinder, S. L.
Published: (2013)

Phosphodiesterase Inhibitors
by: Rui Plácido, et al.
Published: (2019-01-01)

Phosphodiesterase 5 attenuates the vasodilatory response in renovascular hypertension.
by: Johannes Stegbauer, et al.
Published: (2013-01-01)

Cannot write session to /tmp/vufind_sessions/sess_hi3k1l5ncvs3s0g4jo60u079ct